Kari Schmidt

Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach

Structure and function of the blood–brain barrier

The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease

Establishment of a Human Blood-Brain Barrier Co-culture Model Mimicking the Neurovascular Unit Using Induced Pluri- and Multipotent Stem Cells

A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress

Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems

Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

Oral bioavailability of P‐glycoprotein substrate drugs do not differ betweenABCB1‐1Δ andABCB1 wild type dogs

P-Glycoprotein Contributes to the Blood-Brain, but Not Blood-Cerebrospinal Fluid, Barrier in a Spontaneous Canine P-Glycoprotein Knockout Model

The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice